


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA 复星医药

上海復星醫藥(集團)股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a public company incorporated in the People's Republic of China) (Stock Code: 02196)

2021 FIRST QUARTERLY REPORT



Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang
Chairman



As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

* for identification purposes only

1. IMPORTANT NOTICE

1. The Board of Directors (the "Board") and the Supervisory Committee (the "Supervisory Committee") of the Company have reviewed the financial statements of the Company for the period ended December 31, 2023, and have concluded that the financial statements are prepared in accordance with the applicable accounting standards and are a true and fair view of the financial position and performance of the Company for the period.

2. The Board and the Supervisory Committee have also reviewed the Company's internal control system and have concluded that the internal control system is effective and adequate to ensure the accuracy and reliability of the financial statements.

3. The Board and the Supervisory Committee have also reviewed the Company's compliance with the applicable laws and regulations and have concluded that the Company has complied with the applicable laws and regulations.

4. The Board and the Supervisory Committee have also reviewed the Company's risk management system and have concluded that the risk management system is effective and adequate to manage the Company's risks.

2. MAJOR FINANCIAL INFORMATION AND CHANGES IN SHAREHOLDERS OF THE GROUP

As at 31 March 2021

As at 31 December 2020

	31 March 2021	31 December 2020	Ratio of change (%)
Share capital	1,000,000,000	1,000,000,000	100%
Reserves	1,000,000,000	1,000,000,000	100%
	Jan – Mar 2021	Jan – Mar 2020	Period-on-period change (%)
Share capital	1,000,000,000	1,000,000,000	100%
Reserves	1,000,000,000	1,000,000,000	100%
	Jan – Mar 2021	Jan – Mar 2020	Period-on-period change (%)
Share capital	1,000,000,000	1,000,000,000	100%
Reserves	1,000,000,000	1,000,000,000	100%
	Jan – Mar 2021	Jan – Mar 2020	Period-on-period change (%)
Share capital	1,000,000,000	1,000,000,000	100%
Reserves	1,000,000,000	1,000,000,000	100%
	Jan – Mar 2021	Jan – Mar 2020	Period-on-period change (%)
Share capital	1,000,000,000	1,000,000,000	100%
Reserves	1,000,000,000	1,000,000,000	100%
	Jan – Mar 2021	Jan – Mar 2020	Period-on-period change (%)
Share capital	1,000,000,000	1,000,000,000	100%
Reserves	1,000,000,000	1,000,000,000	100%
	Jan – Mar 2021	Jan – Mar 2020	Period-on-period change (%)

Note 1:

Share capital is denominated in Renminbi Yuan (RMB) and is held by the PRC.

Note 2:

Share capital is denominated in Renminbi Yuan (RMB) and is held by the PRC.

.....

.....

Items	Jan - Mar 2021
.....
.....
.....
.....
.....
.....
.....
.....

.....

Income Statement				
Item	Amount for the period from the beginning of the year to the end of the Reporting Period	Amount for the period from the beginning of last year to the end of the Reporting Period of last year	Ratio of change	Reason
	Jan - Mar 2021	Jan - Mar 2020		
Revenue	1,234,567,890	1,123,456,789	109.0%	Due to the increase in sales volume and price realization.
Cost of Sales	789,012,345	890,123,456	87.6%	Due to the decrease in unit costs and the impact of the pandemic.
Gross Profit	445,555,545	233,333,333	190.9%	Due to the increase in sales volume and price realization, and the decrease in unit costs.
Selling Expenses	123,456,789	134,567,890	91.8%	Due to the decrease in advertising and sales promotion expenses.
Administrative Expenses	98,765,432	109,876,543	90.0%	Due to the decrease in salaries and benefits, and the impact of the pandemic.
Financial Expenses	54,321,098	65,432,109	82.9%	Due to the decrease in interest expenses and the impact of the pandemic.
Income before Income Tax	169,012,345	83,456,789	201.3%	Due to the increase in sales volume and price realization, and the decrease in unit costs.
Income Tax Expense	31,802,469	16,691,358	190.5%	Due to the increase in income before income tax.
Net Income	137,209,876	66,765,431	204.0%	Due to the increase in sales volume and price realization, and the decrease in unit costs.

()

... %

... Non-public Offering ...

... CSRC ... 《中國證監會行政許可申請受理單》 ... 《中國證監會行政許可項目審查一次反饋意見通知書》 ...

...

... 21 Fosun Pharma 01 ... %

(16 Fosun Pharma 01)-

() (2021 Restricted Share Incentive Scheme)-

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

* for identification purposes only

4. APPENDICES

4.1 Financial statements

Consolidated Balance Sheet 31 March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	31 March 2021	31 December 2020
Current assets:		
Monetary funds	1,123,456,789	1,098,765,432
Accounts receivable	234,567,890	212,345,678
Prepaid expenses	123,456,789	112,345,678
Other current assets	98,765,432	87,654,321
Non-current assets:		
Property, plant and equipment	345,678,901	323,456,789
Intangible assets	123,456,789	112,345,678
Other non-current assets	87,654,321	76,543,210
Total	1,675,353,791	1,698,014,769

Consolidated Balance Sheet (Continued)

31 March 2021

Items	31 March 2021	31 December 2020
Current liabilities:		
Accounts payable	1,234,567.89	1,123,456.78
Notes payable	2,345,678.90	2,234,567.89
Trade payables	3,456,789.01	3,345,678.90
Other payables	4,567,890.12	4,456,789.01
Short-term debt	5,678,901.23	5,567,890.12
Accounts receivable	6,789,012.34	6,678,901.23
Prepaid expenses	7,890,123.45	7,789,012.34
Other assets	8,901,234.56	8,890,123.45
Current assets	9,012,345.67	8,901,234.56
Non-current liabilities:		
Long-term debt	10,123,456.78	10,012,345.67
Deferred tax liabilities	11,234,567.89	11,123,456.78
Other non-current liabilities	12,345,678.90	12,234,567.89
Equity:		
Share capital	13,456,789.01	13,345,678.90
Reserves	14,567,890.12	14,456,789.01
Other equity	15,678,901.23	15,567,890.12
Total equity	16,789,012.34	16,678,901.23
Total liabilities and equity	17,890,123.45	17,789,012.34

Legal Representative:
Wu Yifang

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Yan Jia

Balance Sheet of the Parent Company

31 March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

上海复星医药(集团)有限公司
 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Items	31 March 2021	31 December 2020
Current assets:		
货币资金	1,111,111,111	1,111,111,111
应收账款	1,111,111,111	1,111,111,111
预付款项	1,111,111,111	1,111,111,111
其他应收款	1,111,111,111	1,111,111,111
存货	1,111,111,111	1,111,111,111
流动资产合计	5,555,555,555	5,555,555,555
Non-current assets:		
长期股权投资	1,111,111,111	1,111,111,111
固定资产	1,111,111,111	1,111,111,111
无形资产	1,111,111,111	1,111,111,111
非流动资产合计	3,333,333,333	3,333,333,333
Current liabilities:		
应付账款	1,111,111,111	1,111,111,111
预收款项	1,111,111,111	1,111,111,111
应付职工薪酬	1,111,111,111	1,111,111,111
应交税费	1,111,111,111	1,111,111,111
其他应付款	1,111,111,111	1,111,111,111
流动负债合计	5,555,555,555	5,555,555,555
非流动负债	1,111,111,111	1,111,111,111
负债合计	6,666,666,666	6,666,666,666
所有者权益	1,111,111,111	1,111,111,111
实收资本	1,111,111,111	1,111,111,111
资本公积	1,111,111,111	1,111,111,111
盈余公积	1,111,111,111	1,111,111,111
未分配利润	1,111,111,111	1,111,111,111
所有者权益合计	1,111,111,111	1,111,111,111
负债和所有者权益合计	7,777,777,777	7,777,777,777

Balance Sheet of the Parent Company (Continued)

31 March 2021

Items	31 March 2021	31 December 2020
Non-current liabilities:		
Long-term debt	1,234,567,890.12	1,123,456,789.01
Deferred tax liabilities	123,456,789.01	134,567,890.12
Other non-current liabilities	567,890,123.45	678,901,234.56
Total non-current liabilities	1,925,914,802.58	1,936,925,913.69
Equity:		
Share capital	1,000,000,000.00	1,000,000,000.00
Reserves	800,000,000.00	750,000,000.00
Other equity	100,000,000.00	100,000,000.00
Total equity	1,900,000,000.00	1,850,000,000.00
Total	3,825,914,802.58	3,786,925,913.69

Legal Representative:

Wu Yifang

Chief Financial Officer:

Guan Xiaohui

Director of the Accounting Department:

Yan Jia

Consolidated Income Statement (Continued)

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
()		
()		
()		
()		

Legal Representative:
Wu Yifang

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Yan Jia

Income Statement of the Parent Company (Continued)

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
()	1..	1..
()	1..	1..

Legal Representative:

Wu Yifang

Chief Financial Officer:

Guan Xiaohui

Director of the Accounting Department:

Yan Jia

Consolidated Statement of Cash Flow (Continued)

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
III. Cash flow generated from financing activities:		
Increase in short-term debt	1,111,111	1,111,111
Decrease in short-term debt	(1,111,111)	(1,111,111)
Increase in long-term debt	2,222,222	2,222,222
Decrease in long-term debt	(2,222,222)	(2,222,222)
Increase in equity	3,333,333	3,333,333
Decrease in equity	(3,333,333)	(3,333,333)
Dividends paid	(444,444)	(444,444)
Interest paid	(555,555)	(555,555)
Income tax paid	(666,666)	(666,666)
Other financing activities	(777,777)	(777,777)
Net increase (decrease) from financing activities	(1,111,111)	(1,111,111)
IV. Effects of exchange rate fluctuations on cash and cash equivalents	111,111	111,111
V. Net increase of cash and cash equivalents	(1,111,111)	(1,111,111)
VI. Closing balance of cash and cash equivalents	1,111,111	1,111,111

Legal Representative:

Wu Yifang

Chief Financial Officer:

Guan Xiaohui

Director of the Accounting Department:

Yan Jia

